Optivise Advisory Services’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$507K Buy
3,946
+474
+14% +$55.5K 0.26% 104
2026
Q1
$418K Sell
3,472
-546
-14% -$63K 0.25% 99
2025
Q4
$423K Buy
4,018
+1,129
+39% +$106K 0.24% 105
2025
Q3
$242K Buy
+2,889
New +$238K 0.14% 155
2025
Q2
Sell
-2,300
Closed -$206K 217
2025
Q1
$206K Sell
2,300
-56
-2% -$5.23K 0.12% 184
2024
Q4
$234K Sell
2,356
-109
-4% -$11.2K 0.13% 151
2024
Q3
$280K Buy
2,465
+76
+3% +$9.03K 0.15% 129
2024
Q2
$296K Buy
+2,389
New +$308K 0.16% 129

Other funds holding MRK

Optivise Advisory Services's MRK Position: Q2 2026 in Review

Optivise Advisory Services increased its Merck (MRK) stake by 14% in Q2 2026, buying an estimated $55.5K and bringing the position to 3,946 shares worth $507K. The position accounts for 0.26% of the portfolio, ranked #104.

Optivise Advisory Services first reported a position in MRK in Q2 2024 and has held it in 8 quarters since. 1,344 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Optivise Advisory Services held 3,946 shares of Merck worth $507K as of Q2 2026.
  • Optivise Advisory Services bought 474 Merck shares in Q2 2026, an estimated $55.5K.
  • Merck made up 0.26% of Optivise Advisory Services's portfolio in Q2 2026, its #104 holding.
  • Optivise Advisory Services first reported a position in Merck in Q2 2024 and has held it in 8 quarters since.
  • 1,344 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Optivise Advisory Services's 13F filing for Q2 2026, filed 13 Jul 2026.